Fujian Haixi Pharmaceuticals Nets HK$940 Million in Hong Kong IPO Ahead of Trading Debut

MT Newswires Live
10/20

Fujian Haixi Pharmaceuticals (HKG:2637) raised HK$940.1 million in net proceeds from its initial public offering in Hong Kong, following a delay in the disclosure of the allocation results, which were supposed to be released on Oct. 16.

The commercial-stage pharmaceutical company earlier said IPO results disclosure was hampered by the lack of time to finalize its listing announcement and secure regulatory clearance.

The final offer price of the deal was set at HK$86.40 per share, the top end of the price range, according to an after-market Hong Kong bourse filing on Friday.

The Hong Kong public offer was 3,165.1 times oversubscribed, and the company issued 1,150,000 shares under this component, the same number as the initial allocation.

The international offering was 6.3 times subscribed, maintaining the size of the allocation under this component at 10,350,000 shares.

Cornerstone investor Harvest International Premium Value (Secondary Market) Fund SPC, acting on behalf of and for the account of Harvest Oriental SP, subscribed to 1,981,700 shares, comprising 17.23% of the offer shares.

Fujian Haixi Pharma will make its trading debut on the bourse Monday, Oct. 20.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10